(Q34327857)

1 August 2017

title

Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. (English)

1 reference

1 August 2017

main subject

Klebsiella pneumoniae

0 references

carbapenem antibiotic

0 references

4

Pierluigi Viale

1 reference

1 August 2017

2

Maddalena Giannella

1 reference

1 August 2017

3

Russell Lewis

1 reference

1 August 2017

1

Nicola Petrosillo

1 reference

1 August 2017

publication date

1 February 2013

1 reference

Expert Review of Anti-infective Therapy

1 August 2017

published in

1 reference

1 August 2017

volume

11

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

159-177

1 reference

Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Management of antibiotic resistance in the intensive care unit setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Antimicrobial resistance among and therapeutic options against gram-negative pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Combination therapy for treatment of infections with gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

The emerging NDM carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Chromosome-encoded ambler class D beta-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Antibiotic dosing in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Colistin pharmacokinetics: the fog is lifting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Dosing of colistin-back to basic PK/PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Intravenous colistimethate administration and colistin lung tissue concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Clinical pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Tigecycline pharmacokinetic/pharmacodynamic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Pharmacokinetics and pharmacodynamics of antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Optimizing use of aminoglycosides in the critically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Suboptimal aminoglycoside dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Fosfomycin: use beyond urinary tract and gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Rifampin combination therapy for nonmycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Improving known classes of antibiotics: an optimistic approach for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.162

21 January 2018

Identifiers

DOI

10.1586/ERI.12.162

1 reference

1 August 2017

1 reference